

ASSOCIATION OF
NORTHERN CALIFORNIA ONCOLOGISTS
observes

BREAST CANCER AWARENESS MONTH

by sponsoring a talk for oncologists and oncology nurses entitled

NEW TAXANE-BASED STRATEGIES
IN THE CHEMOTHERAPY OF
ADVANCED AND EARLY STAGE BREAST CANCER
with

Andrew D. Seidman, M.D.

*Associate Professor of Medicine, Department of Medicine
Joan & Sanford I Weill Medical College of Cornell University;
Attending Physician, Division of Solid Tumor Oncology
Breast Cancer Medicine Service, Department of Medicine
Memorial Sloan-Kettering Cancer Center*

OBJECTIVES

- Understand the utility and limitations of existing chemotherapeutic agents and regimens in the treatment of metastatic breast cancer, and overview the clinical developmental process by which new agents are integrated into breast cancer management.
- Critically review issues of dose and schedule as they relate to the optimal systemic therapy metastatic breast cancer, distinguishing dose-intense from dose-dense scheduling, and focusing on combination versus single agent therapy.
- Address the key trials that have integrated the taxanes into management of metastatic breast cancer, with a focus on nanoparticle albumin-bound paclitaxel.
- Review the present status of adjuvant and neoadjuvant taxane-based chemotherapy for patients with early stage breast cancer.
- Overview the integration of the monoclonal antibodies trastuzumab and bevacizumab into breast cancer treatment.

This talk is scheduled for:

6:30PM Buffet Dinner; 7:00PM Lecture
Tuesday, October 17th

Lafayette Park Hotel • 3287 Mount Diablo Boulevard • Lafayette • (925) 283-3700

Please call the meeting location for directions. FAX your reservation(s) to
José Luis González, *ANCO Executive Director*, at (415) 472-3961
no later than Friday, October 13th.

This event is supported by a grant from *Abraxis Oncology*.

I/We will attend Dr. Seidman’s talk (please print clearly)

Name(s): _____ Tel(s): _____
